Site notifications

Sub menu

 
 

Metalyse (tenecteplase) shortage collection

This content collection relates to the shortage in Australia that was resolved in October 2024

In August 2022, pharmaceutical company Boehringer Ingelheim advised us of a shortage of Metalyse (tenecteplase) injection - a medicine used to dissolve blood clots (thrombolysis) in the immediate period following a heart attack.

The shortage was due to manufacturing capacity constraints following increases in global demand. During the shortage, Australian health services carefully managed supply. 

The shortage was resolved in October 2024.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Visit the Medicine shortage reports database to search for all medicines in shortage and find information about management actions.

6 result(s) found, displaying 1 to 6

Help us improve this page